爱康集团与多家全球知名医疗企业达成战略合作 - 2021年11月09日

The Beijing-based iKang Healthcare Group said the China International Import Expo offers a great opportunity to reach agreements with world-leading medical companies to enhance the effects and efficiency of health checks.

During CIIE, iKang signed an agreement with Mammotome to introduce high-tech early-stage breast cancer screening technology.

Mammotome is the developer of the world's most advanced minimally invasive biopsy system for breast lumps. "Introducing such high-tech diagnostic technology can ensure earlier, more effective and more accurate detection of breast cancer for women's health and safety, as breast cancer is the top female cancer in China," said Zhang Ligang, president of iKang.